# An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

> **NCT02531126** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 877 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** RPC1063

## Key facts

- **NCT ID:** NCT02531126
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-02
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 877 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531126, "An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02531126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*